TNFRSF8 and T-cell non-Hodgkin lymphoma: Ho et al. demonstrated that administration of anti-CD26 monoclonal antibody resulted in cell cycle arrest and inhibition of tumor proliferation of human CD30+ ALC T-cell lymphoma, suggesting potential clinical benefit of anti-CD26 antibody therapy in CD26+ hematological malignancies as well as potentially CD26+ cancers in general [46].